Oh, yeah Celts. How could I have forgotten about that nagging toxic inventory? It just about killed this stock, wiping out most of the Core. And it could very well have caused the company to default on debt, miss the speciality pharmacy opportunity, engage in more rounds of toxic debt, issuing over 100 million shares or more, increasing the AS to 500 million, and then doing a 1:60 reverse split. Well, I have no idea what everyone else is thinking, but I just do not see those risks anymore.

I read a question somewhere asking why anyone would ever sell a business for $550K that essentially has unlimited potential. Good question...maybe the harsh NJ winters forced the prior owners to a sunny and warm residence in AZ. I believe I also read a request for the pharmacy's pre-acquisition financial records to determine how much that company made under its prior management. Frankly, I could care less. I care about today and the future of this specialty pharmacy business. Indeed, I now see revenues that have already experienced substantial increases from the day Team Scrips took over. I see nothing to prevent the pharmacy from hitting $2 million in monthly revenues by the end of the year, about 50% of which I believe will be paid to Scrips after the pharmacy is paid on the invoices totaling $2 million.

Of course, let's not forget about RapiMeds in China and Hong Kong, as well as PIMD and WholesaleRx. This is no one-trick pony.

Thanks again to Celts for leading me to this diamond in the rough, and thanks as well to Bob Schneiderman for not only recognizing hidden opportunities but also for fighting off the toxic debt and executing on your promise to the SCRC!!